Stealthy Third Rock startup poaches oncology exec from Novartis — just days after his boss jumped ship
Novartis’ oncology research unit has lost another top exec to biotech’s lure.
Peter Hammerman, the global head of oncology translational research at NIBR, revealed his jump just days after word got out that his former boss Jeff Engelman has launched a cancer R&D biotech with Loxo founder Josh Bilenker.
His new title is CSO of MOMA Therapeutics, the stealthy Third Rock startup that has been beefing up its C-suite under CEO and Millennium vet Asit Parikh.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,500+ biopharma pros reading Endpoints daily — and it's free.